Stromal rewiring driven by inflammation and CAFs are promising therapeutic targets (65), and our GRN analysis suggests that the JAK-STAT pathway may regulate WNT5A expression (Fig. 5, N and O), opening up the possibility for JAK-STAT inhibitors in treating BCC patients (66). Here, WNT5A is linked to skin basal cell carcinoma.